Gossamer Bio, Inc. (NASDAQ:GOSS) earns a spot on our list of the best penny stocks set to explode<\/strong>.<\/p>\n As of April 8, 2026, sentiment around Gossamer Bio, Inc. (NASDAQ:GOSS) remains cautious, with 56% of covering analysts issuing \u201cHold\u201d ratings on the stock. The consensus price target of $1 implies an upside of 203.31%.<\/p>\n Gossamer Bio, Inc. (NASDAQ:GOSS) drew attention from analysts following its Q4 and full-year 2025 earnings release.<\/p>\n On March 23, 2026, Cantor Fitzgerald lowered Gossamer Bio, Inc. (NASDAQ:GOSS) from \u201cOverweight\u201d to \u201cNeutral,\u201d following the unsatisfactory Phase 3 PROSERA readout. The price target reduction came because of an increasingly uncertain regulatory path for seralutinib in pulmonary arterial hypertension, which the analyst said was too unclear to warrant conviction in commercialization.<\/p>\n This cautionary approach was noted in Gossamer\u2019s fourth-quarter and full-year 2025 update on March 17, 2026, where management said it was reviewing the PROSERA dataset, engaging with the FDA, and reevaluating its strategy and capital allocation.<\/p>\n Seralutinib showed a placebo-adjusted 6MWD improvement of 13.3 meters in Week 24, along with stronger signals in certain subgroups. However, the study failed to meet its prespecified alpha threshold.<\/p>\n Additionally, Gossamer Bio, Inc. (NASDAQ:GOSS) halted enrollment in PH-ILD\u2019s Phase 3 SERANATA study and reported $136.9 million in cash, cash equivalents, and marketable securities as of the end of 2025, with the expectation that it will fund operations into Q1 of 2027.<\/p>\n Gossamer Bio, Inc. (NASDAQ:GOSS) is a pharmaceutical company specializing in the discovery, development, and marketing of treatments in the medical fields of immunology, inflammation, and oncology.<\/p>\n While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/strong>.<\/p>\n<\/div>\n<\/div>